Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen, Willemijn J; Ossenkoppele, Rik; Knol, Dirk L; Tijms, Betty M; Scheltens, Philip; Verhey, Frans R J; Visser, Pieter Jelle; Aalten, Pauline; Aarsland, Dag; Alcolea, Daniel; Alexander, Myriam; Almdahl, Ina S; Arnold, Steven E; Baldeiras, Inês; Barthel, Henryk; van Berckel, Bart N M; Bibeau, Kristen; Blennow, Kaj; Brooks, David J; van Buchem, Mark A; Camus, Vincent; Cavedo, Enrica; Chen, Kewei; Chetelat, Gael; Cohen, Ann D; Drzezga, Alexander; Engelborghs, Sebastiaan; Fagan, Anne M; Fladby, Tormod; Fleisher, Adam S; van der Flier, Wiesje M; Ford, Lisa; Förster, Stefan; Fortea, Juan; Foskett, Nadia; Frederiksen, Kristian S; Freund-Levi, Yvonne; Frisoni, Giovanni B; Froelich, Lutz; Gabryelewicz, Tomasz; Gill, Kiran Dip; Gkatzima, Olymbia; Gómez-Tortosa, Estrella; Gordon, Mark Forrest; Grimmer, Timo; Hampel, Harald; Hausner, Lucrezia; Hellwig, Sabine; Herukka, Sanna-Kaisa; Hildebrandt, Helmut

Published in:
JAMA: the journal of the American Medical Association

DOI:
10.1001/jama.2015.4668

2015
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
A Meta-analysis

Willemijn J. Jansen, MSc; Rik Ossenkoppele, PhD; Dirk L. Knol, PhD; Betty M. Tijms, PhD; Philip Scheltens, MD, PhD; Frans R. J. Verhey, MD, PhD; Pieter Jelle Visser, MD, PhD; and the Amyloid Biomarker Study Group

Importance  Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.

Objective  To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).

Data Sources  Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.

Study Selection  Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.

Data Extraction and Synthesis  Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.

Main Outcomes and Measures  Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.

Results  The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.

Conclusions and Relevance  Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.

Corrected on May 19, 2015.

Author Affiliations: Author affiliations are listed at the end of this article.

Authors/Group Information: Members of the Amyloid Biomarker Study Group are listed at the end of the article.

Corresponding Author: Willemijn J. Jansen, MSc, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, PO Box 616, 6200 MD, Maastricht, the Netherlands (willemijn.jansen@maastrichtuniversity.nl) and Pieter Jelle Visser, MD, PhD (pj.visser@maastrichtuniversity.nl).
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

Original Investigation Research

May 19, 2015 Volume 313, Number 19

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

As most published studies did not provide prevalence estimates according to age and other risk factors, we asked study contact persons to provide participant-level data or tabulated data according to 10-year age categories and unpublished data if available. Tabulated data were converted to participant-level data with the average age in the age category. The quality of primary articles from each study was systematically assessed using relevant criteria from the STROBE14 and QUADAS15 guidelines (eTable 1 in the Supplement). All participants gave written informed consent to participate. Studies were approved by the local ethics committees of the participating centers.

Data Collection and Operationalization

Information on study procedures was extracted from the publication or requested from the study contact person and used to create a common set of variables.

Cognitive Status, APOE, Sex, and Education

Normal cognition was defined as normal scores on cognitive tests, the absence of cognitive complaints for which medical help was sought, or both. Subjective cognitive impairment was defined as presence of a cognitive complaint with presentation at a health care facility but normal cognition on tests. Mild cognitive impairment was defined according to published criteria.16,17 These include a decline in memory or another cognitive domain reported by the patient, informant, or both and objectively verified by neuropsychological testing, in combination with no or minimal impairment in activities of daily living and not meeting criteria for dementia. Mild cognitive impairment was subclassified as amnestic MCI or nonamnestic MCI when possible. Information on APOE-ε4 carrier status (yes/no), APOE genotype, and years of education was retrieved. To describe the association of APOE genotype with age, we reported for each genotype the age at which 15% of the participants with normal cognition were amyloid positive as a proxy for first appearance of abnormal amyloid.

Setting and Recruitment

The study setting was classified as clinical if patients presented with cognitive complaints at a health care facility; research if patients were asked to participate in research by recruitment through advertisements or from other hospital departments; population-based if a random sample of the general population was included; or mixed if participants were recruited from a combination of settings.

Amyloid Assessment

Measurement details documented included amyloid tracer and assessment via visual scales or quantitative measures for PET studies and assay used to measure amyloid-β1-42 levels for CSF studies. Positron emission tomography and CSF biomarkers were dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. (See eTables 2 and 3 in the Supplement for measurement details.) For participants who had both PET and CSF amyloid measures, we selected the first amyloid measure in time.

Methods

To identify relevant biomarker studies, the MEDLINE and Web of Science databases were searched for studies published before April 2015. The search terms used for PET studies were PET and (Pittsburgh or PIB or florbetapir or AV-45 or florbetaben or flutemetamol) and (amyloid or abeta). The search terms used for CSF studies were (CSF or cerebrospinal fluid) and (amyloid or abeta). Titles and abstracts were reviewed and relevant studies were retrieved. Searches were restricted to articles published in the English language. Studies were included if amyloid biomarker data for participants without dementia were reported and an a priori defined cutoff for amyloid abnormality was used. Studies that included participants with neurological, psychiatric, or other diseases that might affect the central nervous system were excluded. We also asked partners from 2 European multicenter collaborative projects, BIOMARKAPD and EMIF-AD, to provide unpublished data (Figure 1).

Figure 1

Copyright 2015 American Medical Association. All rights reserved.
Comparison With Prevalence of AD-Type Dementia

Age- and APOE-specific prevalence data of AD-type dementia were obtained through a meta-analysis or from published lifetime risk data for AD-type dementia\(^\text{18}\) as described in the eMethods in the Supplement.

**Number Needed to Screen**

To use the prevalence estimates in selecting participants at risk for amyloid positivity for AD prevention studies, numbers needed to screen to identify 1 amyloid-positive participant were calculated as described in the footnote of eTable 6 in the Supplement.

**Statistical Analysis**

We conducted a meta-analysis with individual participant data, in which original research data were sought directly from study contact persons, combined, and reanalyzed centrally. Generalized estimating equations (GEEs) were used to estimate the prevalence and odds ratios (ORs). Generalized estimating equations allow for analysis of binary correlated data such that participant-level data on the prevalence from all studies could be modeled while simultaneously accounting for the clustering of participants within studies. We assumed a logit link function for binary outcome with an exchangeable correlation structure to account for within-study correlation. Analyses were performed using SPSS version 20.0 (IBM) with the genlin command. They were conducted using the total study population unless specified otherwise.

The main analyses were performed with cognitive status (normal cognition, SCI, MCI), age, sex, education, and APOE-\(\epsilon4\) genotype as independent variables. Age was entered as a continuous measure centered at the median. Educational level was dichotomized at the median (high, \(\geq 14\) years, vs moderate to low, \(<14\) years). Secondary analyses tested associations with biomarker modality, MCI subtype, published vs unpublished studies, setting, and recruitment strategy while adjusting for cognitive status, age, and APOE-\(\epsilon4\) carrier status. We tested 2-way and 3-way interactions between variables and age as a quadratic term, and
these were retained in the equation in case of a significant Wald statistic as indicated in table footers and figure legends. Analyses were repeated using natural cubic splines with knots at ages 50, 60, 70, and 80 years, but this did not improve the model. Estimated probabilities and 95% confidence intervals from the GEE analyses were used in tables. Probabilities estimated by GEE were compared with the observed probabilities in 5-year age groups.

The extent of between-study variability was investigated in several ways. In the total sample, the random intercept variance related to study was estimated in a random-effects analysis with the independent variables age, APOE-ε4 carrier status, cognitive status, and interactions using the xtmelogit function from Stata version 12.0 (StataCorp). This variance was expressed as an intraclass correlation coefficient. In diagnostic and APOE subgroups, heterogeneity within 5-year age strata was assessed with the $I^2$ statistic from a random-effects meta-analysis in Stata version 12.0. An $I^2$ statistic value greater than 50% was considered indicative for substantial heterogeneity. Center variability across the age range was visualized by plotting the prevalence for studies with more than 50 participants.

Significance level was set at $P < .05$ in 2-sided tests, uncorrected for multiple comparisons. When associations changed after correcting for multiple comparisons with the Bonferroni method, this was mentioned in the text or table. R version 3.1.2 (R Foundation for Statistical Computing) and GraphPad Prism version 6.0 (GraphPad Software) were used for graphs with estimated probabilities and 95% confidence intervals from the GEE analyses.

## Results

The literature search resulted in 7578 publications; amyloid was assessed by PET in 890 and by CSF in 6688. From these, 599 were selected for full-text review. We identified 47 studies from the European multicenter projects (Figure 1). A total of 91 unique studies met inclusion criteria; the authors of 55 studies agreed to share data. Contact persons from 54 studies provided participant-level data and 1 provided tabulated data ($n = 137$). Of the 36 studies for which contact persons refused or did not reply, 31 were selected through the literature search and 5 from the European multicenter studies. Characteristics of the 31 excluded published studies did not differ from those of the 55 included studies (eTable 4 in the Supplement).

### Study Characteristics

Of the selected studies, 45 were single-center and 10 were multicenter studies. (eTable 5 in the Supplement shows detailed study information.) Forty-one studies provided data for participants with normal cognition, 20 for patients with SCI, and 47 for patients with MCI. Of the MCI studies, 8 classified patients with MCI as amnestic MCI or nonamnestic MCI, 10 studies only included patients with amnestic MCI, and all other studies used a broad MCI definition or did not specify MCI subtype. Information on APOE-ε4 carrier status was provided by 41 studies and information on APOE genotype by 37 studies. All studies but 1 specified the sex of the participants. Information on years of education was available from 44 studies. Studies contributing data for participants with normal cognition were performed in a research setting in 95% ($n = 39$), selection through advertisements in 15, from hospitals in 10, and from other or unknown sources in 14 and a mixed setting in 5% ($n = 2$). Forty-six of the studies (98%) that included patients with SCI or MCI were performed in a clinical setting.

Amyloid-PET data were provided by 29 studies. Of these, 22 studies used $[^{11}C]Pittsburgh compound-B (PiB), 9[^{18}F]florbetapir, 2[^{18}F]florbetaben, and 1[^{18}F]flutemetamol, including 5 that used multiple tracers. Eleven studies assessed the PET images by visual scales whereas 16 studies used quantitative assessment and 2 studies used both methods. Cerebrospinal fluid amyloid-$\beta_{42}$ data were provided by 31 studies. The Innotest enzyme-linked immunosorbent assay (Fujirebio Europe) was used for CSF analysis in 29 studies and the xMAP Luminex assay in 2 studies. Two studies (1111 participants) provided data on both PET and CSF amyloid measures. Primary studies were assessed with the quality rating criteria, and typically met all criteria, although bias could not be assessed in 37 publications and participant flow remained unclear in 2 publications (eTable 1 in the Supplement).

### Participant Characteristics

We included 7583 participants from 55 studies, of whom 2914 (38%) had normal cognition, 697 (9%) SCI, and 3972 (52%) MCI. Amyloid positivity was assessed with PET for 2370 participants (31%; 1346 normal cognition, 35 SCI, 989 MCI) and with CSF for 5213 participants (69%; 1568 normal cognition, 662 SCI, 2983 MCI). Baseline characteristics according to cognitive status are shown in Table 1. Participants with missing APOE data did not differ in amyloid positivity and sex with participants with APOE data but more often had limited education (63%) compared with participants who had these data available (48%, $\chi = 62.5, P < .001$). Participants with missing sex or education data did not differ in amyloid positivity, sex, or education, and APOE-ε4 carrier status from participants with these data.

### Prevalence of Amyloid Positivity

Estimated probabilities of amyloid positivity according to cognitive status, APOE-ε4 status, and age are displayed in Figure 2, Figure 3A and B, and Table 2. Observed prevalence estimates are shown in Table 3. The difference between the observed and predicted prevalence rates was less than 10% in more than 90% of the comparisons indicating good model fit. Amyloid positivity was about twice as common in patients with MCI compared with participants with normal cognition (mean difference, 25% [95% CI, 22% to 28%]; $P < .001$) or SCI (mean difference, 23% [95% CI, 14% to 32%]; $P < .001$), while it did not differ between participants with normal cognition and SCI (mean difference, 2% [95% CI, –6% to 10%]; $P = .62$). Amyloid positivity increased with age in all diagnostic groups.
Table 1. Baseline Study Participant Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Normal Cognition (n = 2914)</th>
<th>SCI (n = 697)</th>
<th>MCI (n = 3972)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (SD), y</td>
<td>Mean (13.2)</td>
<td>64.2 (8.0)</td>
<td>70.2 (8.7)</td>
</tr>
<tr>
<td>Age groups, No. (%), y</td>
<td>&lt;40</td>
<td>140 (4.8)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td></td>
<td>40-44</td>
<td>28 (1.0)</td>
<td>3 (0.4)</td>
</tr>
<tr>
<td></td>
<td>45-49</td>
<td>80 (2.7)</td>
<td>12 (1.7)</td>
</tr>
<tr>
<td></td>
<td>50-54</td>
<td>178 (6.1)</td>
<td>48 (6.9)</td>
</tr>
<tr>
<td></td>
<td>55-59</td>
<td>258 (8.9)</td>
<td>158 (22.7)</td>
</tr>
<tr>
<td></td>
<td>60-64</td>
<td>361 (12.4)</td>
<td>170 (24.4)</td>
</tr>
<tr>
<td></td>
<td>65-69</td>
<td>530 (18.2)</td>
<td>126 (18.1)</td>
</tr>
<tr>
<td></td>
<td>70-74</td>
<td>567 (19.5)</td>
<td>103 (14.8)</td>
</tr>
<tr>
<td></td>
<td>75-79</td>
<td>380 (13.0)</td>
<td>56 (8.0)</td>
</tr>
<tr>
<td></td>
<td>80-84</td>
<td>263 (9.0)</td>
<td>16 (2.3)</td>
</tr>
<tr>
<td></td>
<td>85-89</td>
<td>102 (3.5)</td>
<td>4 (0.6)</td>
</tr>
<tr>
<td>≥90</td>
<td>27 (0.9)</td>
<td>0</td>
<td>19 (0.5)</td>
</tr>
<tr>
<td>Sex, No. (%)</td>
<td>Female</td>
<td>1537 (55.0)</td>
<td>348 (49.9)</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>1259 (45.0)</td>
<td>349 (50.1)</td>
</tr>
<tr>
<td>Education by category, No. (%)</td>
<td>&lt;14 y</td>
<td>815 (35.7)</td>
<td>356 (66.0)</td>
</tr>
<tr>
<td></td>
<td>≥14 y</td>
<td>1465 (64.3)</td>
<td>183 (34.0)</td>
</tr>
<tr>
<td>MMSE score*</td>
<td>Mean (SD)</td>
<td>29.0 (1.3)</td>
<td>28.4 (1.5)</td>
</tr>
<tr>
<td>Assessment by PET biomarker</td>
<td>Assessment by CSF biomarker</td>
<td>1346 (46.2)</td>
<td>35 (5.0)</td>
</tr>
<tr>
<td>Biomarker abnormal, No. (%)</td>
<td>1568 (53.8)</td>
<td>662 (95.0)</td>
<td>2983 (75.2)</td>
</tr>
<tr>
<td>APOE-ε4 carrier status, No. (%)</td>
<td>ε2ε2</td>
<td>328 (24.4)</td>
<td>8 (22.8)</td>
</tr>
<tr>
<td></td>
<td>CSF β amyloid</td>
<td>415 (26.5)</td>
<td>144 (21.8)</td>
</tr>
<tr>
<td>APOE-ε4 negative, No. (%)</td>
<td>APOE-ε4 positive</td>
<td>1614 (70.5)</td>
<td>322 (60.4)</td>
</tr>
<tr>
<td>APOE genotype, No. (%)</td>
<td>ε2ε3</td>
<td>255 (12.0)</td>
<td>49 (9.2)</td>
</tr>
<tr>
<td></td>
<td>ε2ε4</td>
<td>41 (1.9)</td>
<td>13 (2.4)</td>
</tr>
<tr>
<td></td>
<td>ε3ε3</td>
<td>1228 (57.7)</td>
<td>272 (51.0)</td>
</tr>
<tr>
<td></td>
<td>ε3ε4</td>
<td>531 (24.9)</td>
<td>178 (33.4)</td>
</tr>
<tr>
<td></td>
<td>ε4ε4</td>
<td>65 (3.1)</td>
<td>20 (3.8)</td>
</tr>
</tbody>
</table>

Abbreviations: APOE, apolipoprotein E; CSF, cerebrospinal fluid; SCI, subjective cognitive impairment; MMSE, Mini Mental State Examination; PET, positron emission tomography; SCI, subjective cognitive impairment.

APOE-ε4 carriers had 10% to 40% higher absolute prevalence estimates than noncarriers in each diagnostic group (Table 2, Figure 3A and B). At the median age of 70 years, the prevalence estimates were different between all APOE genotypes in participants with normal cognition, except for those of the ε2ε4 and ε3ε4 genotypes, which did not differ from each other (mean difference ε4ε4 vs ε3ε4, 38% [95% CI, 22% to 53%]; P < .001, vs ε2ε4, 28% [95% CI, 7% to 49%]; P = .008, vs ε3ε2, 60% [95% CI, 44% to 75%]; P < .001, vs ε2ε2, 73% [95% CI, 58% to 87%]; P < .001; mean difference ε3ε4 vs ε2ε4, 9% [95% CI, −1% to 20%]; P = .08, vs ε3ε3, 22% [95% CI, 18% to 26%]; P < .001, vs ε2ε3, 35% [95% CI, 29% to 40%]; P < .001; mean difference ε2ε4 vs ε3ε3, 31% [95% CI, 21% to 42%]; P < .001, vs ε2ε3, 44% [95% CI, 31% to 57%]; P < .001; mean difference ε3ε3 vs ε2ε3, 13% [95% CI, 8% to 17%]; P < .001) (Figure 3C).

After correction for multiple comparisons, ε2ε4 and ε4ε4 showed no statistically significant difference (P = .08). None of the 10 participants with ε2ε2 were amyloid positive. APOE genotype was associated with the age at onset of amyloid positivity. For example, the age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers,
and 95 years for ε2ε3 carriers. In patients with SCI, prevalence of amyloid pathology according to APOE genotype was similar to participants with normal cognition in all age groups (mean difference, 1% [95% CI, −11% to 12%; P = .92]). In patients with MCI, the prevalence differed between genotypes at the median age of 70 years, while again the ε2ε4 and ε3ε4 genotypes did not differ from each other; the difference between the ε2ε4 and ε3ε3 genotypes was not statistically significant (mean difference ε4ε4 vs ε3ε4, 23% [95% CI, 17% to 29%]; P < .001, vs ε2ε4, 33% [95% CI, 14% to 51%]; P = .001, vs ε3ε3, 54% [95% CI, 47% to 60%]; P < .001, vs ε2ε3, 64% [95% CI, 57% to 71%]; P < .001; mean difference ε3ε4 vs ε2ε4, 10% [95% CI, −9% to 28%]; P = .31, vs ε3ε3, 31% [95% CI, 25% to 37%]; P < .001, vs ε2ε3, 41% [95% CI, 34% to 48%]; P < .001; mean difference ε2ε4 vs ε3ε3, 21% [95% CI, −8% to 43%]; P = .06, vs ε2ε3, 31% [95% CI, 9% to 53%]; P = .005; mean difference ε3ε3 vs ε2ε3, 10% [95% CI, 6% to 14%]; P < .001) (Figure 3D).

Patients with MCI and the APOE ε2ε2 genotype were not included in the analysis because of the small sample size (n = 5, of whom 1 was amyloid positive). The prevalence of amyloid pathology in patients with MCI at age 70 years was 89% (95% CI, 81%-94%) for ε4ε4 carriers, 66% (95% CI, 60%-72%) for ε3ε4 carriers, 57% (95% CI, 35%-76%) for ε2ε4 carriers, 35% (95% CI, 31%-40%) for ε3ε3 carriers, and 25% (95% CI, 19%-32%) for ε2ε3 carriers. Table 4 shows the ORs for amyloid positivity of the APOE genotypes relative to the ε3ε3 genotype at age 70 years for participants with normal cognition and MCI.

The prevalence of amyloid pathology at the mean age was 5% higher (95% CI, 1% to 8%; P = .005) in participants with an education above the median (n = 2530) than in those with education below the median (n = 2415) regardless of cognitive status, age, and APOE-ε4 carrier status (eFigure 1 in the Supplement). There was no significant association with or interaction between sex and any of the risk factors for amyloid positivity (mean difference, 1% [95% CI, −1% to 3%]; P = .52).

Comparison With Prevalence of AD-Type Dementia

The age-related increase in amyloid positivity in participants with normal cognition paralleled age-specific AD-type dementia prevalence estimates, with an intervening period of about 20 years (Figure 4A). Similarly, APOE genotype–specific estimates of amyloid positivity paralleled APOE genotype–specific lifetime risks of AD-type dementia with a difference of 25 to 30 years (Figure 4B).

Number Needed to Screen

The numbers of participants needed to screen (NNS) to identify 1 amyloid-positive person are displayed according to age, cognitive status, and APOE genotype in eTable 6 in the Supplement. The NNS varied from 1.0 (95% CI, 1.0-1.1), for persons with normal cognition or MCI who were older than 70 years with the APOE ε4ε4 genotype, to 16.7 (95% CI, 11.1-25.0), for persons with normal cognition aged 50 years without an APOE-ε4 allele. If APOE genotype is unknown, participants need to be screened for this first. The number of participants for whom APOE genotyping needs to be performed to find 1 participant with that particular APOE genotype who is amyloid positive varied between 3.5 (95% CI, 2.8-4.3), for persons with normal cognition aged 90 years without an APOE-ε4 allele, to 89.6 (95% CI, 64.5-129.0), for persons with normal cognition aged 50 years with the APOE ε4ε4 genotype.

Assessment of Study-Related Heterogeneity

In the total study population, the intraclass correlation coefficient for study-related random intercept variance was 0.085, indicating minor heterogeneity among studies. Within age, APOE-ε4, and diagnostic subgroups, heterogeneity was not substantial according to the F statistic, except for 2 of 54 subgroups (50%-60% in age group 65-69 years of SCI APOE-ε4 carriers and in age group 75-79 years of MCI APOE-ε4 noncarriers) (eTable 7 in the Supplement).

Visual inspection of variability in prevalence estimates across age in studies with at least 50 participants also indicated that between-study variability was small (eFigure 2 in the Supplement).

Post Hoc Analyses

The biomarker used to assess amyloid positivity was not associated with prevalence (mean difference, 0% [95% CI, −7% to 8%]; P = .87) for participants with normal cognition or MCI (n = 6885). Patients with SCI were excluded because amyloid was measured with PET in only 5% of participants. While adjusting for APOE-ε4 carrier status and age, amyloid prevalence at the mean age was higher in patients with amnestic MCI (n = 1405) than in patients with nonamnestic MCI (n = 225, 58% [95% CI, 48% to 67%] vs 47% [95% CI, 35% to 60%], mean difference, 11% [95% CI, 0% to 21%]; P = .03) and higher in patients with nonamnestic MCI than in participants with normal cognition (n = 2289, mean difference, 15% [95% CI, 2% to 28%]; P = .03). The prevalence
Discussion

This amyloid biomarker study including individuals without dementia provides prevalence estimates of amyloid pathology over an age range of 18 to 100 years for persons with normal cognition, SCI, and MCI. The age at onset of amyloid positivity was associated with cognitive status and the APOE genotype. At age 90 years, about 40% of the APOE-e4 noncarriers and more than 80% of APOE-e4 carriers with normal cognition were amyloid positive. Amyloid positivity was associated with education but not with sex or biomarker modality. The age-related prevalence of amyloid positivity in participants with normal cognition paralleled the age-related prevalence of AD-type dementia in the general population in an APOE genotype–specific way with a time lag of 20 to 30 years.

Patients with MCI had 20% to 30% higher prevalence estimates of amyloid positivity than those with normal cognition or SCI, supporting the view that MCI is a risk state for AD.\textsuperscript{16} Cognitively normal and SCI groups did not differ in amyloid positivity, suggesting that the presence of SCI in a memory clinic population might not be associated with an increased risk for AD. Previous studies in other settings showed inconsistent results regarding differences in amyloid positivity between cognitively normal and SCI participants.\textsuperscript{20,21}
ing that further research is needed on this. Patients with nonamentic MCI had lower prevalence estimates of amyloid positivity than patients with amnestic MCI but higher than participants with normal cognition. This suggests that both amnestic MCI and nonamentic MCI are associated with an increased risk for AD and that this risk is higher for patients with amnestic MCI. The observation that a substantial number of patients with MCI were not amyloid positive, even at older age, suggests that the MCI phenotype does not always have AD as underlying pathology. Possible non-AD causes in MCI may be hippocampal sclerosis, mild depression, or vascular damage.

Age was a risk factor for amyloid positivity, which is in line with the finding that age is an important risk factor for postmortem amyloid load\(^2\) and for AD-type dementia.\(^2\) as also shown in Figure 4A. The prevalence of amyloid positivity in participants with normal cognition aged 50 to 60 years was somewhat higher than found in an earlier population-based study that was not included in our analysis.\(^2\) This could relate to differences in recruitment strategy and assessment.

Relative to the APOE-\(\varepsilon3\) allele, the APOE-\(\varepsilon4\) risk allele was associated with a greater risk for amyloid positivity and de-
increased age at onset, while the APOE-ε2 allele had the opposite associations. This is similar to the relation of APOE genotype with the risk for AD-type dementia and age at onset of AD-type dementia as reported in clinical studies25,26 and the APOE genotype–specific lifetime risk for AD as shown in Figure 4B. The high prevalence of amyloid positivity in participants with normal cognition and MCI with ε2ε4 in the present study indicates that the detrimental relation of amyloid positivity with ε4 outweighs the protective association with ε2, in line with clinical AD studies.27 The OR for amyloid pathology of the APOE genotypes relative to the ε3ε3 genotype was similar to the OR for AD-type dementia in case-control studies.18,27 The strong association of the APOE genotype with amyloid positivity emphasizes APOE as an important target for treatment studies.28,29

Highly educated participants had a higher prevalence of amyloid pathology than those with less formal education. This may seem in contrast with the finding that high education level is associated with a lower risk for AD-type dementia30 but is in agreement with the cognitive reserve hypothesis.31 According to this hypothesis, nondemented individuals with a high level of education have a greater cognitive reserve such that they can sustain more amyloid pathology before developing dementia. Education itself was not associated with the ex-

### Table 4. Odds Ratios for the Association Between APOE Genotype and Amyloid Positivity at Age 70 Years

<table>
<thead>
<tr>
<th>APOE Genotype</th>
<th>Normal cognition</th>
<th>MCI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>ε3ε3</td>
<td>1 [Reference]</td>
<td>1 [Reference]</td>
</tr>
<tr>
<td>ε2ε3</td>
<td>0.34 (0.23-0.51)</td>
<td>0.59 (0.48-0.73)</td>
</tr>
<tr>
<td>ε2ε4</td>
<td>4.29 (2.67-6.90)</td>
<td>2.38 (0.98-5.81)</td>
</tr>
<tr>
<td>ε3ε4</td>
<td>2.94 (2.34-3.70)</td>
<td>3.52 (2.73-4.55)</td>
</tr>
<tr>
<td>ε4ε4</td>
<td>18.76 (5.47-64.37)</td>
<td>14.50 (8.14-25.81)</td>
</tr>
</tbody>
</table>

**P values**

- Normal cognition: ε3ε3 vs ε2ε3: <.001, ε2ε4 vs ε3ε3: <.001, ε3ε4 vs ε3ε3: <.001, ε4ε4 vs ε3ε3: <.001.
- MCI: ε3ε3 vs ε2ε3: <.001, ε2ε4 vs ε3ε3: <.001, ε3ε4 vs ε3ε3: <.001, ε4ε4 vs ε3ε3: <.001.

**No. amyloid positive (%)**

- Normal cognition: ε3ε3 vs ε2ε3: 275 (22.4%), ε2ε4: 22 (8.6%), ε3ε4: 17 (41.5%), ε4ε4: 213 (40.1%), ε2ε3: 45 (69.2%)
- MCI: ε3ε3 vs ε2ε3: 490 (38.7%), ε2ε4: 57 (27.0%), ε3ε4: 35 (56.5%), ε4ε4: 666 (67.2%), ε2ε3: 261 (86.7%)

**Abbreviations:** APOE, apolipoprotein E; OR, odds ratio; MCI, mild cognitive impairment.

* The ORs were generated from generalized estimating equations separately in participants with normal cognition and MCI. The models included age, APOE genotype, an interaction between age and APOE genotype, and a quadratic age term in the normal cognition model as predictors. P values represent the significance of the OR for amyloid positivity compared with the ε3ε3 genotype. The ε2ε2 genotype was excluded because of the small number of participants in this group.

Figure 4. Comparison of the Prevalence of Amyloid Positivity With the Prevalence of and Lifetime Risks for Alzheimer Disease-Type Dementia

**A** Prevalence of Alzheimer disease and amyloid positivity

**B** Lifetime risk of Alzheimer disease and amyloid positivity by APOE genotype

The prevalence estimates in panel A were estimated from a meta-analysis of 14 studies (eMethods in the Supplement). The prevalence estimates in panel B of amyloid positivity in participants with normal cognition are plotted against published lifetime risks for Alzheimer disease (AD)-type dementia by APOE genotype (adapted from Genin et al36).
tent of pathology at postmortem examination\textsuperscript{32} but might modify the relationship between AD pathology and expression of dementia,\textsuperscript{39} resulting in higher amyloid positivity prevalence in nondemented highly educated participants. An alternative explanation would be that highly educated persons with amyloid pathology may be overrepresented in study participation or clinical care seeking due to self-selection bias.

Our finding that the prevalence of amyloid positivity was the same for men and women is in line with a previous neuropathological study showing no difference in neuritic and diffuse plaque load between men and women.\textsuperscript{34} This finding is also in agreement with another earlier study,\textsuperscript{35} as is our finding that there was no interaction between sex and APOE-e4 carrier status on amyloid positivity.

Although PET and CSF are thought to measure different types of amyloid-\(\beta\),\textsuperscript{36} we did not find differences in amyloid positivity estimates for PET and CSF biomarkers. This is in line with published high concordance rates of 84\% to 92\% between the 2 biomarkers.\textsuperscript{37,38} Also, high levels of agreement have been reported for studies that provided more than 50 participants to our study in whom amyloid was assessed with both PET and CSF.\textsuperscript{39,40}

We pooled data from a large number of studies, and this may have introduced bias because of differences in the methods underlying amyloid assessment, cutoff definition, participant selection, diagnostic criteria, and other aspects of study design. However, in the total study sample; in age, APOE, and diagnostic subgroups; and on visual inspection of study-specific prevalences over age, there was limited evidence for study-related heterogeneity, which supports the pooling of data from different studies (eFigure 2 and eTable 7 in the Supplement). Moreover, the Alzheimer’s Association Quality Control program for CSF biomarkers reported that overall concordance for diagnostic classification was high between centers despite analytical variance.\textsuperscript{41} We also explored the association of a number of study characteristics with the prevalence in post hoc analyses, but no relation was found. An advantage of participant-level analysis over aggregated pooling is that the power to detect subgroup effects is increased,\textsuperscript{42} while the risk for ecological bias is decreased.\textsuperscript{43}

A limitation of this study is that our participants with normal cognition were mostly recruited via advertisements, making this sample vulnerable to self-selection bias\textsuperscript{44} and restricting generalizability to the general population. Participants with SCI and MCI were mostly recruited from clinical settings, rendering them dissimilar from these individuals in the general population. Participants with significant comorbid disorders are usually excluded from participation, and studies often used standardized cognitive screens, which also affects generalizability. Although MCI was not classified as amnestic or non-amnestic for most participants, our findings indicate that we mostly included amnestic MCI patients because the prevalence estimates in amnestic MCI patients did not differ from those with a broad or unspecified definition of MCI. Still, patients with nonamnestic MCI had a lower prevalence than patients with amnestic MCI, suggesting that this is an important distinction to make in future research. Moreover, our prevalence estimates are based on cross-sectional data. The lifetime risk for individuals without dementia to develop amyloid pathology will be higher than the cross-sectional estimate at any age because amyloid-positive persons may die or progress to dementia at follow-up.

This study has several implications for understanding the development of AD. The observation that key risk factors for AD-type dementia are also risk factors for amyloid positivity in cognitively normal persons provides further evidence for the hypothesis that amyloid positivity in these individuals reflects early AD. Further support for this hypothesis comes from other studies that show that amyloid positivity in nondemented individuals is associated with memory impairment, cognitive decline, increased amyloid deposition and brain atrophy rates, and mortality.\textsuperscript{45-48} Our study also indicates that development of AD pathology can start as early as age 30 years, depending on the APOE genotype. Comparison with prevalence and lifetime risk estimates of AD-type dementia suggests a 20- to 30-year interval between amyloid positivity and dementia, implying that there is a large window of opportunity to start preventive treatments. Still, the exact interval between the onset of amyloid positivity and onset of AD-type dementia needs to be assessed by long-term follow-up studies because not all persons with amyloid pathology will become demented during their lifetime,\textsuperscript{49} and not all individuals with a clinical diagnosis of AD-type dementia have amyloid pathology. Because of the uncertainty about whether and when an amyloid-positive individual without dementia will develop dementia, amyloid positivity in these individuals should not be equated with impending clinical dementia but rather be seen as a risk state. Our prevalence rates can be used as an inexpensive and noninvasive approach to select persons at risk for amyloid positivity.

Conclusions

Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by PET imaging or CSF findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.

ARTICLE INFORMATION

Authors/Amloid Biomarker Study Group

members include the byline authors as well as the following individuals: Pauline Aalten, PhD; Dag Aarsland, MD, PhD; Daniel Alcolea, MD; Myriam Alexander, PhD; Ina S. Almdahl, MD; Steven E. Arnold, MD; Inês Baldeiras, PhD; Henriky Barthel, MD, PhD; Bart N. M. van Berckel, MD, PhD; Kristen Bibeau, PhD; Kaj Blennow, MD, PhD; David J. Brooks, MD, PhD; Mark A. van Buchem, MD, PhD; Vincent Camus, MD, PhD; Enrica Cavedo, MSc; Kewei Chen, PhD; Gael Chetelat, PhD; Ann D. Cohen, PhD; Alexander Drzezga, MD, PhD; Sebastiaan Engelborghs, MD, PhD; Anne M. Fagan, PhD; Tormod Fladby, MD, PhD; Adam S. Fleisher, MD; MAS; Wieje M. van der Flier, PhD; Lisa Ford, MD; Stefan Förster, MD, PhD; Juan Fortea, PhD; Nadia Fosset, MD, PhD; Kristin S. Frederiksen, MD, PhD; Yvonne Freund-Levi, MD, PhD; Giovanni B. Frisoni, MD, PhD; Lutz Froehlich, MD, PhD; Tomasz Gabryelewicz, MD, PhD; Kiran Dip Gill, PhD; Olympia Gkatzina, MSc; Estrella Gómez-Tortosa, MD, PhD;
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

Melbourne, Australia (Rowe, Villemagne); Valdecilla, IDIVAL, Santander, Spain (Rodríguez-Service, Universitary Hospital Marqués de la Coruna, Department of Neurology, Getafe, Spain); Postgraduate Department of Medicine, Nuffield Hospital, Edinburgh, Scotland (Nordberg); Department of Psychological Medicine, Institute of Psychiatry, Kings College London, London, United Kingdom (Peters); Department of Psychiatry and Psychotherapy, Charité Berlin, Germany (Peters); Department of Psychiatry, Service of Old Age Psychiatry and Department of Clinical Neurosciences, Leenaards Memory Centre, University Hospital of Lausanne, Lausanne, Switzerland (Popp); Postgraduate Institute of Medical Education and Research (PGIMER), Department of Neurology, Neuhr Hospital, Chandigarh, India (Prabhakaran); Turku PET Centre and Division of Clinical Neurosciences Turku, University of Turku and Turku University Hospital, Turku, Finland (Rinne); Center for Vital Longevity, University of Texas at Dallas (Rogge); Neurology Service, Vall d’Hebron University Hospital, Barcelona, Spain (Rodríguez-Service); Department of Nuclear Medicine and Centre for PET, AI. Stockholm, Sweden (Mattsson); Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands (Ossenkoppele); Department of Neurology, Memory and Aging Center, University of California, San Francisco (Ossenkoppele); Helen Wills Neuroscience Institute, University of California, Berkeley (Ossenkoppele); Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands (Knol).

Author Contributions: Ms Jansen and Dr Visser had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Jansen, Ossenkoppele, Verhey, Visser.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Jansen, Visser.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Jansen, Knol, Visser.

Administrative, technical, or material support: All authors.

Study supervision: Visser.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Scheltens reported receiving grants from GE Healthcare, Piramal, and Merck, paid to his institution. Dr Verhey reported receiving compensation as a speaker and consultant for Nutricia Advanced Medical Food. Dr Visser reported receiving grants from the EU and the French Ministry of Health. Dr Aarsland reported having received research support or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, and GE Health. Dr Alexander reported being an employee of Roche Products. Dr Pathel reported receiving speaker and consultant honoraria as well as travel expenses from Piramal Imaging (Berlin) and personal fees from NCTA Medical Food. Dr Bibeau reported being a share-holding employee of GlaxoSmithKline. Dr Blennow reported receiving personal fees (advisory board) from Roche Diagnostics. Dr Blennow reported receiving research grants from Roche Diagnostics. Dr Chen reported receiving grants from the National Institutes of Health (NIH). Dr Drazega reported receiving payments for consulting on Alzheimer’s disease. Dr Parnell reported receiving grants from the National Institutes of Health (NIH) and the Alzheimer’s Association. Dr Dugue reported receiving payments for consulting on Alzheimer’s disease.

Copyright 2015 American Medical Association. All rights reserved.
Research Original Investigation
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(florbetaben FIB) as an amyloid-beta PET imaging agent. Dr. Kornhuber reported having received grants from German Federal Ministry of Education and Research (BMBF); Kompetenzzentren Demenzen (O1G1O420) and German Federal Ministry of Education and Research (BMBF): The Frontotemporal-Lobar Degeneration Consortium (FTDL-C), O1G1D007A and having a patent, PCT/ EP2004/003963, “Diagnosis of Alzheimer’s disease,” issued; a patent, EP B181034 A1, “Large Aβ-peptide binding particles (LAPs) in diagnosis and therapy of Alzheimer’s dementia,” issued; a patent, WO 2007/082750 A1, “Immunoglobulin-bound Ab-peptides and immunoglobulins-binding Ab-peptides in diagnosis and therapy of Alzheimer’s disease,” issued; and a patent, EP 2437067A2, “Methods of differentially diagnosing dementias,” issued; and a patent, “New formulations for diagnosis of Alzheimer’s disease,” pending. Dr. Van Laere reported having received grants from Merck, Janssen Pharmaceuticals, and GE Healthcare and having received personal fees from Biogen IDEC, Genentech, and Synarc. Dr. Lleo reported having received grants from Instituto de Salud Carlos III (Fondo de Investigación Sanitaria, PI10/01878, PI10/01532, PI11/2425, PI11/3035 and the CIBEREPD program). Dr. Mroczko reported having received grants from the Lundbeck Foundation, Danish Medical Research Council, and Rigshospitalet. Dr. Meyer reported having received money from GE Healthcare for an ongoing research study (IIT). Dr. Mintun reported being an employee of Avid Radiopharmaceuticals, a wholly owned subsidiary of El Lilly. Dr. Morris reported having received grants from NIH (PS0AG005681, PO1AGO03391, PO1AGO026276, U19AG032438). Dr. Mroczko reported having received grants and personal fees from the Leading National Research Centre (KNOW), Medical University of Białystok, Poland. Dr. Novak reported being an employee of Janssen Research and Development and holding stock in the same. Dr. Parasekova reported having received grants from European Union (European Regional Development Fund [ERDF]) and Greek national funds through the Operational Program “Competitiveness and Entrepreneurship” of the National Strategic Reference Framework (NSRF) Research Funding Program: Joint Programming Neurodegenerative Disease, “Biomarkers for Alzheimer’s disease and Parkinson’s disease.” Dr. Peters reported having received grants and/or personal fees from Lilly, Roche, Genentech, Lundbeck, Affiris, Piramal, Novartis, and Txr-Pharmaceuticals. Dr. Popp reported having received grants from the Swiss National Science Foundation. Dr. Rabinoivci reported having received grants from Avid Radiopharmaceuticals and personal fees from Genentech. Dr. Rinne reported having received grants from Sigrid Juselius Foundation and Turku University Hospital clinical grants. Dr. Rot reported having received grants from JPNP BIOMARKAP. Dr. Rowe reported having received grants from Avid Radiopharmaceuticals, Piramal Imaging, AstreaZeneca, GE Healthcare, AviLilly, Navidea, CSIRO, NHMRC, Alzheimer’s Association, and an anonymous foundation and having had a patent licensed for PET image processing. Dr. Sabri reported having received grants and/or personal fees from Piramal Imaging, Bayer Healthcare, and Siemens Healthcare. Dr. Sarzin reported having received personal fees from Novartis (lecture) and Allianz (lecture). Dr. Soininen reported having received grants from the Academy of Finland, European Union Seventh Framework Programme (FP7-2007-2013) (grant agreement No. 223073; Aβ-amyloid imaging), and having had a patent licensed for PET image processing. Dr. Svinning reported having received grants and personal fees from GE Healthcare and CSIRO, NHMRC, Alzheimer’s Association, and an anonymous foundation and having had a patent licensed for PET image processing. Dr. Teunissen reported having been a member of the international advisory board at Innogenetics and Roche; having received free kit-reagents for experiments from JBL; Innogenetics, MesoScale Discovery, Invitrogen, Euroimmun, and FluidX; having received research contracts at Probiodrug, JBL, and Abbott. Dr. Vandenbergh reported having received clinical trial agreements with GEHC, Merck, Forum, and Roche; grants from Research Foundation—Flanders (FWO) and IU Leuven; and nonfinancial support from GEHC. Dr. Verbeken reported having served on an advisory board for Roche. Dr. Waldemar reported being a board member of the Lundbeck Foundation. Dr. Anders Wallin reported having received speakers’ bureau fees from Esai and Triolab and serving on the advisory board for Nutricia and Esai. Dr. Wolk reported having received personal fees from GE Healthcare and Piramal Pharma and grants from Avid Radiopharmaceuticals. The authors received compensation (ie, salary) as employees of their respective organizations. No other disclosures were reported.

Funding/Support: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement No. 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution. BLAST participated in an EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The project is supported through national funding organizations under the aegis of JPND (http://www.jpnd.eu). In the Netherlands, this is ZonMW. The DESCRIPTA study was funded by the European Commission within the 5th framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission as part of the 6th framework programme (contract No. 376/70). This research was performed within the framework of the Center for Translational Molecular Medicine (CTMM) (http://www.ctmm.nl), project Learkin (grant O2012). The AIBL study was funded in part by the study partners (Australian Commonwealth Scientific Industrial Research Organization [CSIRO], Edith Cowan University [ECU], Mental Health Research Institute [MHRI], Alzheimer’s Australia [AA], National Ageing Research Institute [NARI], Austin Health, CoGstate, Hollywood Private Hospital, Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the National Health and Industry Endowment Fund (SIEF). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG249260) and the US Department of Defense ADNI (W81XWH-09-2-0002 and -0003). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica; Biogen IDEC; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly; F. Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics; IXICO; Janssen Alzheimer’s Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Medpace; Merck; Meso Scale Diagnostics; NeuroRx Research; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The Dementia Competence Network (DCN) has been supported by a grant from the German Federal Ministry of Education and Research (BMBF); Kompetenzzentren Demenzen (O1G1O420). Additional funding related to the randomized clinical trials came from Janssen-Cilag and Merz Pharmaceuticals. The latter funds were exclusively used for personnel, pharmaceuticals, blistering, and shipment of medication; monitoring and as capitation fees for recruiting centers. Funding source for the Chadigarh study is the Indian Council of Medical Research (ICMR), India. Funding for the St Louis contribution was provided by the National Institute on Aging (PS0 AG055681, P01 AG03991, and P01 AG026276); Fred Simmons and Olga Mohan, and the Charles and Joanne Knight Alzheimer’s Research Initiative of the Washington University Knight Alzheimer’s Disease Research Center. The Tours study received financial support of the French Ministry of Health grant PHRC-N-2008 1004 and the EC-FP6-project DIMI, LSHB CT-2005 512146. The Caen study was funded by Agence Nationale de la Recherche, Programme Hospitalier de Recherche Clinique, Région Basse Normandie, and Institut National de la Santé et de la Recherche Médicale (Inserm). The research leading to the Munich contribution to the Mattsson multicenter study has received funding from the program “Investissements d’avenir” (ANR-10-IAHU-06). The study from Pittsburgh was supported by National Institutes of Health grants (PS0 AG005133, R37 AG025516, P01 AG025204). The New York contributions to the Mattsson multicenter study were in part supported by P30 AG020851, R01 AG13616, R01 AG22374, and R01 AG12101. Data from Brescia in this article were collected by Translational Outpatient Memory Clinic (TOMC) working group at IRCCS Fatebenefratelli in Brescia, Italy. Contributors to the TOMC are G. Amorosi, S. Archeitti, L. Behl, E. Garain, L. Bocchio-Chiavetto, C. Bonvicini, E. Canu, F. Caobelli, E. Cavedo, E. Chittio, M. Cotelli, M. Gennarelli, S. Galluzzi, C. Geroldi, R. Ghidoni, R. Giubbini, U. P. Guerra, G. Kuffenschi, G. Lugiosi, D. Moretti, B. Paghera, M. Parapini, C. Portieri, M. Romano, S. Rosini, I. Rovaris, R. Zanardini, and O. Zanetti. The JPND Project is supported in Italy by the Italian Ministry of Health. The assembling of the TU Munich data set was supported in part by the German research foundation (Deutsche Forschungsgemeinschaft) (HE 4560/1-2, DR 445/3-1 and DR 445/4-1 to A.D.), and by a KfK grant for clinical research of the Technische Universität München (to A.D. and T.G.). The Florbetaben phase 2 study from which data

Copyright 2015 American Medical Association. All rights reserved.
were derived for this multicenter evaluation was sponsored by Bayer Healthcare/Piramal Imaging (Berlin, Germany). This work was supported by the University of Antwerp Research Fund; the Alzheimer Research Foundation (SAO-FRA); the Research Foundation Flanders (FWO); the Agency for Innovation by Science and Technology (IWT); the Belgian Science Policy Office Interuniversity Attraction Pole (IAP) program; and the Flemish Government-initiated Methusalem excellence grant.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors’ respective organizations were given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

Disclaimer: Any views expressed in this publication represent the personal opinions of the authors and not those of their respective employers.

Additional Contributions: We acknowledge Gabriel Miltenberger-Miltényi and André Janiero (Institute of Molecular Medicine, Lisbon) for quantification of CSF biomarkers assembled in the Lisbon contribution. Neither individual was compensated for the contribution besides salary. Multicenter studies involved in this project included the following: European Medical Information Framework-Alzheimer Disease (EMIF-AD); Biomarkers for Alzheimer Disease and Parkinson Disease (BIOMARKAD); Alzheimer’s Disease Neuroimaging Initiative (ADNI); Australian Imaging, Biomarkers & Lifestyle (AIBL) study; Avid Pharmaceuticals multicenter study for the AV45-A17 Study Group; Development of Screening Guidance for Dominantly Inherited Alzheimer’s Disease (DESCIRPA) study; German Dementia Competence Network (DCN); European Beta Amyloid Oligomers in the Early Diagnosis of AD and as Marker for Treatment Response (EDAR) study; Florbetaben (FBB) Phase 2 multicenter study; Leiden Alzheimer Research Network (LeARN) project; Mattsson et al (2009) multicenter study; Multicenter study by UK Hospitals and University Hospital of Turku. Part of the data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. Additional information is available in the Supplement.

Correction: This article was corrected online May 19, 2015, to fix curves in Figure 3C.

REFERENCES